What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?

被引：3

作者：

Betensky, Marisol ^{[1
,2
,7
]}

Monagle, Paul ^{[3
,4
]}

Male, Christoph ^{[5
]}

Goldenberg, Neil A. ^{[1
,2
,6
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD USA

[2] Inst Clin & Translat Hosp, St Petersburg, FL USA

[3] Univ Melbourne, Haematol Res Murdoch Childrens Res Inst, Royal Childrens Hosp, Dept Clin Haematol,Dept Paediat, Melbourne, Vic, Australia

[4] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia

[5] Med Univ Vienna, Dept Pediat, Vienna, Austria

[6] Johns Hopkins Univ, Dept Med, Div Hematol, Sch Med, Baltimore, MD USA

[7] Johns Hopkins All Childrens Hosp, Dept Pediat, Div Hematol, 501 6th Ave South, St Petersburg, FL 33701 USA

来源：

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2023年 / 7卷 / 03期

基金：

美国国家卫生研究院;

关键词：

anticoagulants; clinical trials; direct-acting oral anticoagulants; pediatrics; thrombosis; VENOUS THROMBOEMBOLISM; DABIGATRAN ETEXILATE; OPEN-LABEL; THROMBOSIS; CHILDREN; PREVENTION; SAFETY; PROPHYLAXIS; INFORMATION; EFFICACY;

D O I：

10.1016/j.rpth.2023.100140

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A State of the Art lecture titled "What the direct oral anticoagulants (DOACs) trials did and didn't tell us" was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. The use of DOACs in children is of particular interest as they exhibit several advantages over conventional anticoagulation agents most commonly used in pediatrics. To date, several DOAC pediatric investigational programs (PIPs) have been completed, and although they have provided some of the best quality of evidence in pediatric anticoagulation therapy, the data generated by these trials remain limited. Here, we review and summarize the currently available data provided by the DOAC PIPs, provide perspectives on what we have and have not learned from these trials, and how we might leverage this knowledge to optimize the design of future anticoagulant PIPs. Finally, we summarize relevant new data on this topic presented during the 2022 ISTH Congress.

引用

下载

页数：15

共 50 条

[41] What did we learn from animal models in peritoneal dialysis?
Lameire, Norbert
Van Biesen, Wim
Mortier, Siska
DeVriese, An
PERITONEAL DIALYSIS: A CLINICAL UPDATE, 2006, 150 : 70 - 76
[42] What did we learn from the previous coronavirus epidemics and what can we do better: a neuroinfectiological point of view
Akhvlediani, T.
Jelcic, I.
Taba, P.
Pfausler, B.
Steiner, I.
Sellner, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (11) : E69 - E72
[43] What can we learn from "dropouts' in clinical trials?
Schmitt-Egenolf, M.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 318 - 319
[44] Did we learn more about adjuvant chemotherapy? The dark side of data from clinical trials
Oakman, C.
Di Leo, A.
BREAST, 2009, 18 : S2 - S2
[45] Revisiting the 2019 Oranga Tamariki inquiries: What did we learn, and what might that mean for the future of child protection in Aotearoa?
Fitzmaurice-Brown, Luke
AOTEAROA NEW ZEALAND SOCIAL WORK, 2023, 35 (03): : 5 - 18
[46] Discussion 1: What did we learn from the tidal evolution theory?
Zahn, JP
Tidal Evolution and Oscillations in Binary Stars Third Granada Workshop on Stellar Structure, 2005, 333 : 280 - 287
[47] HIRING RELATIVES AS CAREGIVERS: WHAT DID WE LEARN FROM CASH AND COUNSELING?
Simon-Rusinowitz, L.
Loughlin, D. M.
Mahoney, K. J.
GERONTOLOGIST, 2010, 50 : 176 - 176
[48] What Did We Learn from the I-35W Bridge?
Hao, Su
CIVIL ENGINEERING, 2009, 79 (02): : 8 - 8
[49] When the dust settles: what did we learn from the bexarotene discussion?
Tesseur, Ina
De Strooper, Bart
ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (06):
[50] Antiepileptic drugs as mood stabilizers:: What did we learn from the epileptology?
Peter, Rajna
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2008, 61 (9-10): : 305 - 316

← 1 2 3 4 5 →